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INTRODUCTION
Approximately 20% to 30% of invasive breast cancers overexpress or 
amplify human epidermal growth factor receptor-2 (HER-2) protein or 
gene [1,2]. Such tumors are associated with poor prognosis and have 
shown clinical benefits from targeted therapy including trastuzumab 
in the metastatic or adjuvant setting [3,4]. However, many HER-2 
positive breast cancers eventually develop resistance to therapy.
 HER family is composed of 4 members: HER-1 which is also 
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Purpose: This study aimed to compare expression of human epidermal growth factor receptor (HER) family and insulin-like growth fac-
tor-1 receptor (IGF-1R) before and after targeted therapy in HER-2 positive breast cancers.
Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise 
archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of 
them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced dis-
ease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test.
Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 
(53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial 
EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although 
there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor respond-
ers, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demon-
strated discordant results between before and after targeted therapy.
Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance 
mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 tar-
geted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy.
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known as epidermal growth factor receptor (EGFR), HER-2, HER-3, 
and HER-4. Although ligand of HER-2 has not been identified yet, 
heterodimerization of HER-2 with other HER members potently ac-
tivates intracellular signal transduction pathways including mito-
gen activated protein kinase pathway and phosphatidylinositol 
3-kinase (PI3K) pathway [5]. These signals eventually increase cell 
proliferation and motility, accelerate angiogenesis, reduce apopto-
sis, and are associated with tumor invasiveness, metastasis, and 
survival [6]. 
 Several mechanisms have been proposed in relation with de novo 
or acquired resistance to HER-2 targeted therapy. These include al-
teration of binding site of HER-2 to trastuzumab including truncat-
ed HER-2, known as p95-HER-2, activation of alternative signaling 
pathways including insulin-like growth factor-1 receptor (IGF-1R) 
pathway, change in downstream signaling pathways of HER-2 in-
cluding upregulation of PI3K pathway, and failure of an appropriate 
immune-mediated response including low affinity Fc receptor poly-
morphisms [7-9]. However, development or clinical validation of 
therapeutic strategies is still remaining to be determined for over-
coming resistance to HER-2 targeted therapy. In addition, prognos-
tic or predictive biomarkers including HER-2 are known to be possi-
bly discordant between primary and metastatic breast cancers [10]. 
However, information on expression of growth factor receptors 
family other than HER-2, especially before and after administration 
of therapeutic agents, has been limited in Korean breast cancer pa-
tients who received HER-2 targeted therapy.
 The aims of this study were to investigate and to compare ex-
pression of EGFR, HER-3, HER-4, and IGF-1R before and after HER-
2 targeted therapy in primary or metastatic HER-2 positive breast 
cancer patients.
METHODS
Patient selection and clinicopathologic parameters
A total of 28 patients having available archive tissue blocks before 
and after targeted therapy were retrospectively selected from the 
Severance Hospital of Yonsei University College of Medicine, Seoul, 
Republic of Korea, between January 2007 and December 2011. 
HER-2 positive breast cancer patients who had recurrent or meta-
static disease without treatment of targeted agents or who diag-
nosed of disease relapse based on clinico-radiological findings 
alone without tissue confirm were excluded. All patients were his-
tologically confirmed with HER-2 positive invasive breast cancer 
and received systemic chemotherapy combined with trastuzumab, 
tyrosine kinase inhibitors including lapatinib and afatinib, or both.
 Five of 28 patients received targeted therapy in the neoadjuvant 
setting and achieved a pathologic complete response (pCR) after 
definite surgery without recurrence during follow-up. Therefore, 
tissue blocks after targeted therapy were not able to be obtained 
and these 5 patients with a pCR were defined as good responder in 
this study. Of 28 patients, 23 eventually experienced disease pro-
gression or recurrence even though administration of targeted 
therapy and were defined as poor responder in this study. In 23 pa-
tients, a total of 49 formalin-fixed, paraffin-embedded primary or 
metastatic breast cancer tissue blocks were available and obtained 
both before and after targeted therapy. HER-2 targeted therapy 
was administered at the metastatic setting in 6 patients, at the 
neoadjuvant setting in 4 patients, and at the adjuvant setting in 13 
patients. Three tissue blocks were obtained from 3 patients and 
paired 2 blocks were obtained from 20 patients. Finally, 54 tissue 
blocks from 28 patients were analyzed. 
 Clinicopathological information including treatment modalities 
or expression of hormone receptors (HRs) was obtained from the 
review of medical records and pathology reports. Tumors with ≥1% 
nuclear-stained cells by immunohistochemistry were considered 
positive for estrogen receptor (ER) and progesterone receptor (PR) 
according to the American Society of Clinical Oncology/College of 
American Pathologists (ASCO/CAP) guidelines [11]. HER-2 staining 
was scored as 0, 1+, 2+, or 3+ according to ASCO/CAP guidelines 
[12]. In cases with a HER-2 2+ result, fluorescence in situ hybrid-
ization (FISH) was performed using a PathVysion HER2 DNA Probe 
Kit (Vysis, Downers Grove, IL, USA) and HER-2 gene amplification 
was defined as a HER-2 gene/chromosome 17 copy number ratio 
≥2.0 according to ASCO/CAP guidelines [12]. HER-2 was consid-
ered positive in cases with an immunohistochemistry score of 3+ or 
gene amplification by FISH. This study was approved by the Institu-
tional Review Board of Severance Hospital, Yonsei University Health 
System, Seoul, Republic of Korea (IRB No. 4-2013-0390). Written 
informed consent was waived.
Immunohistochemical staining
With reviewing the archival hematoxylin and eosin stained slides, 
immunohistochemistry was performed using the whole sections of 
formalin-fixed, paraffin-embedded tissue blocks. Briefly, 3 µm-thick 
sections were obtained using a microtome and transferred onto ad-
hesive slides. The whole sections were deparaffinized and rehydrat-
ed in usual manner. Antigen retrieval was performed using an elec-
tronic pressure cooker for 10 minutes in Triology buffer (Cell 
Marque Co., Rocklin, CA, USA). After treatment with hydrogen per-
oxide block solution for 10 minutes, background staining was 
blocked by incubation in Ultra V Block solution (Thermo Scientific/
Lab Vision, Fremont, CA, USA) for 5 minutes at room temperature. 
After incubation with primary antibodies against EGFR (diluted 1:75, 
DAK-H1-WT; Dako, Glostrup, Denmark), HER-3 (diluted 1:50, DAK-
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of tumor cells; and 3+, uniform intense membranous staining in at 
least 10% of tumor cells. In this study, arbitrary cutoff was used 
since no consensus existed for determination of EGFR, HER-3, HER-
4, and IGF-1R expression. Staining score of 0 and 1+ was consid-
ered negative result while score of 2+ and 3+ was considered posi-
tive in this study (Fig. 1).
Statistical analysis
The differences between the discrete variables were evaluated by 
the chi-square test. Fisher’s exact test was used when appropriate. 
For the comparison of the means in the case of continuous numeri-
cal data, the independent two samples t-test was used. A P-value 
<0.05 was considered statistically significant. SPSS ver. 20.0 (IBM 
Inc., Armonk, NY, USA) was used for all statistical analyses.
H3-IC; Dako), HER-4 (diluted 1:50, polyclonal; Thermo Scientific), 
and IGF-1R (diluted 1:200, polyclonal; Bioss, Woburn, MA, USA), 
immunodetection was performed using the UltraVision LP detection 
system (Thermo Scientific/Lab Vision) according to the manufactur-
er’s instructions. Color was developed with 3,3´-diaminobenzidine 
and slides were counterstained with Harris hematoxylin. The prima-
ry antibody incubation step was omitted in the negative control.
 Interpretation of immunohistochemical staining was performed 
blinded to clinical data of the patients. Expression of EGFR, HER-3, 
HER-4, and IGF-1R was detected as membrane staining and de-
fined using the following categories in accordance with HER-2 ex-
pression scoring system: 0, no immunostaining; 1+, weak or incom-
plete membrane staining, less than 10% of tumor cells; 2+, com-
plete membranous staining, either uniform or weak in at least 10% 
Fig. 1. Immunohistochemical expression of EGFR, HER-3, HER-4, and IGF-1R in HER-2 positive breast cancer tissues (immunohistochemical 
staining, ×100). (A) Negative and (B) positive results of EGFR, (C) negative and (D) positive results of HER-3, (E) negative and (F) positive re-
sults of HER-4, and (G) negative and (H) positive results of IGF-1R. EGFR, epidermal growth factor receptor; HER, human epidermal growth 
factor receptor; IGF-1R, insulin-like growth factor-1 receptor.
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RESULTS
Mean age at diagnosis was 46.9 years in 28 patients. Stage II, III, 
and IV at initial diagnosis of breast cancer was 14 (50.0%), 11 
(39.3%), and 3 (10.7%) patients, respectively. ER-positive or PR-pos-
itive tumors were 15 (53.6%) patients and HRs-negative tumors 
were 13 (46.4%) patients. Trastuzumab alone was administered in 
19 (67.9%) patients and 9 (32.1%) patients received tyrosine kinase 
inhibitors with or without trastuzumab. Of 54 tissue blocks, 31 
(57.4%) were breast. Locoregional sites were in 9 (16.7%) cases. 
Lung, brain, bone or soft tissues, liver, and ovary were in 6 (11.1%), 4 
(7.4%), 2 (3.7%), 1 (1.9%), and 1 (1.9%) cases, respectively.
 Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R 
was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%) and 14 
(50.0%) patients, respectively. Baseline growth factor receptors sta-
tus, HRs expression and targeted agents were not significantly dif-
ferent between patients with good and poor response to HER-2 
targeted therapy (Table 1). Although there was no statistical signifi-
cance, good responders showed a higher proportion of positive 
HER-3 expression (P=0.062).
 Among 23 poor responders, growth factor receptors family ex-
pression was compared between baseline tissue specimens before 
administration of targeted therapy and resistant tumor tissues after 
administration of targeted therapy. Table 2 shows significant asso-
ciations of EGFR expression in all cases but approximately one-
fourths patients discordantly changed in EGFR expression. On the 
basis of subgroup analysis according to expression of HRs, there 
was no statistically significant association of EGFR expression be-
tween initial and recurrent tumors. According to regimens of tar-
geted agents, EGFR showed a trend of concordant results without 
statistical significance. Comparison of HER-3 expression in all cases 
was determined no significant associations of HER-3 expression. 
Similarly to EGFR expression, approximately one-thirds patients 
discordantly changed in HER-3 expression but a trend of concor-
dant results was noted (Table 3). Interestingly, in subgroups of pa-
tients who received trastuzumab alone, HER-3 expression presented 
Table 1. Comparison of initial growth factor receptors and clinicopathological parameters between patients with good and poor response to 
targeted therapy
Parameter Good responder (n=5) Poor responder (n=23) Total P-valuea)
Age (yr) 48.4± 10.9 46.6± 10.8 46.9± 10.7 0.734b)
EGFR > 0.999
   Negative 2 (40.0) 11 (47.8) 13 (46.4)
   Positive 3 (60.0) 12 (52.2) 15 (53.6)
HER-3 0.062
   Negative 1 (20.0) 16 (69.6) 17 (60.7)
   Positive 4 (80.0) 7 (30.4) 11 (39.3)
HER-4 0.553
   Negative 0 (0) 6 (26.1) 6 (21.4)
   Positive 5 (100) 17 (73.9) 22 (78.6)
IGF-1R 0.326
   Negative 1 (20.0) 13 (56.5) 14 (50.0)
   Positive 4 (80.0) 10 (43.5) 14 (50.0)
Stage at diagnosis 0.796
   II 2 (40.0) 12 (52.2) 14 (50.0)
   III 3 (60.0) 8 (34.8) 11 (39.3)
   IV 0 (0) 3 (13.0) 3 (10.7)
Hormone receptors > 0.999
   ER– and PR– 2 (40.0) 11 (47.8) 13 (46.4)
   ER+ or PR+ 3 (60.0) 12 (52.2) 15 (53.6)
Regimens of targeted therapy > 0.999
   Trastuzumab alone 4 (80.0) 15 (65.2) 19 (67.9)
   TKI± trastuzumab 1 (20.0) 8 (34.8) 9 (32.1)
Values are presented as mean± standard deviation or number (%).
EGFR, epidermal growth factor receptor; HER, human epidermal growth factor receptor; IGF-1R, insulin-like growth factor-1 receptor; ER, estrogen receptor; PR, progesterone re-
ceptor; TKI, tyrosine kinase inhibitor.
a)Fisher’s exact test. b)Independent two samples t-test.
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a pattern of concordant results but many patients showed negative 
HER-3 expression. Table 4 shows a trend of concordant HER-4 re-
sults without statistical significance in all cases but approximately 
one-fourths patients showed discordantly changed in HER-4 ex-
pression. Similarly, in the analysis of IGF-1R, 8 of 23 (34.8%) pa-
tients discordantly changed IGF-1R expression although there was 
no statistically significant association in all cases (Table 5). By sub-
group analysis of HRs-positive tumors, IGF-1R expression showed 
concordant association with borderline significance between base-
line and resistant tumors.
 Four blocks from 2 patients were able to check expression of 
growth factor receptors family before administration of targeted 
Table 2. Comparison of EGFR before and after targeted therapy
Baseline EGFR expression
EGFR status after targeted therapy
P-value
Negative Positive
All cases (n= 23) 0.022
   Negative 8 (72.7) 3 (27.3)
   Positive 3 (25.0) 9 (75.0)
HRs-positive (n= 12) > 0.999a)
   Negative 7 (77.8) 2 (22.2)
   Positive 2 (66.7) 1 (33.3)
HRs-negative (n= 11) 0.345a)
   Negative 1 (50.0) 1 (50.0)
   Positive 1 (11.1) 8 (88.9)
Trastuzumab alone (n= 15) 0.119a)
   Negative 5 (62.5) 3 (37.5)
   Positive 1 (14.3) 6 (85.7)
TKI± trastuzumab (n= 8) 0.196a)
   Negative 3 (100) 0 (0)
   Positive 2 (40.0) 3 (60.0)
EGFR, epidermal growth factor receptor; HRs, hormone receptors; TKI, tyrosine kinase 
inhibitor.
a)Fisher’s exact test.
Table 3. Comparison of HER-3 before and after targeted therapy
Baseline HER-3 
expression
HER-3 status after targeted therapy
P-valuea)
Negative Positive
All cases (n= 23) 0.182
   Negative 12 (75.0) 4 (25.0)
   Positive 3 (42.9) 4 (57.1)
HRs-positive (n= 12) 0.242
   Negative 5 (71.4) 2 (28.6)
   Positive 1 (20.0) 4 (80.0)
HRs-negative (n= 11) > 0.999
   Negative 7 (77.8) 2 (22.2)
   Positive 2 (100) 0 (0)
Trastuzumab alone (n=15) 0.057
   Negative 11 (84.6) 2 (15.4)
   Positive 0 (0) 2 (100)
TKI± trastuzumab (n= 8) > 0.999
   Negative 1 (33.3) 2 (66.7)
   Positive 3 (60.0) 2 (40.0)
HER, human epidermal growth factor receptor; HRs, hormone receptors; TKI, tyrosine 
kinase inhibitor.
a)Fisher’s exact test.
Table 4. Comparison of HER-4 before and after targeted therapy
Baseline HER-4 
expression
HER-4 status after targeted therapy
P-valuea)
Negative Positive
All cases (n= 22) 0.100
   Negative 3 (50.0) 3 (50.0)
   Positive 2 (12.5) 14 (87.5)
HRs-positive (n= 11) 0.491
   Negative 1 (33.3) 2 (66.7)
   Positive 1 (12.5) 7 (87.5)
HRs-negative (n= 11) 0.152
   Negative 2 (66.7) 1 (33.3)
   Positive 1 (12.5) 7 (87.5)
Trastuzumab alone (n= 14) 0.266
   Negative 3 (60.0) 2 (40.0)
   Positive 2 (22.2) 7 (77.8)
TKI± trastuzumab (n= 8) -
   Negative 0 (0) 1 (100)
   Positive 0 (0) 7 (100)
HER, human epidermal growth factor receptor; HRs, hormone receptors; TKI, tyrosine 
kinase inhibitor.
a)Fisher’s exact test.
Table 5. Comparison of IGF-1R before and after targeted therapy
Baseline IGF-1R 
expression
IGF-1R status after targeted therapy
P-valuea)
Negative Positive
All cases (n= 23) 0.221
   Negative 10 (76.9) 3 (23.1)
   Positive 5 (50.0) 5 (50.0)
HRs-positive (n= 12) 0.072
   Negative 6 (85.7) 1 (14.3)
   Positive 1 (20.0) 4 (80.0)
HRs-negative (n= 11) > 0.999
   Negative 4 (66.7) 2 (33.3)
   Positive 4 (80.0) 1 (20.0)
Trastuzumab alone (n=15) 0.329
   Negative 7 (77.8) 2 (22.2)
   Positive 3 (50.0) 3 (50.0)
TKI± trastuzumab (n= 8) > 0.999
   Negative 3 (75.0) 1 (25.0)
   Positive 2 (50.0) 2 (50.0)
IGF-1R, insulin-like growth factor-1 receptor; HRs, hormone receptor; TKI, tyrosine ki-
nase inhibitor.
a)Fisher’s exact test.
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therapy. One patient aged 52-year-old had HRs negative breast can-
cer with simultaneous lung metastasis at initial diagnosis. EGFR, 
HER-3, and HER-4 of primary breast cancer and metastatic lung le-
sion was consistently positive, negative, and positive, respectively. 
However, IGF-1R of breast and lung lesions was positive and nega-
tive, respectively. The other aged 55-year-old had HRs positive tu-
mor. Three years later, lung mass was developed and confirmed as 
metastatic carcinoma by fluoroscopy-guided lung biopsy. HER-3 
alone of breast and lung lesions was consistently negative. EGFR, 
HER-4, and IGF-1R of primary breast lesion was positive, positive, 
and negative, respectively. However, EGFR, HER-4, and IGF-1R of 
metastatic lung lesion was negative, negative, and positive, respec-
tively.
 One patient evaluated biomarkers three times. She was 46 year-
old and had HRs negative tumor. EGFR, HER-3, HER-4, and IGF-1R 
of breast cancer was positive, negative, positive, and positive, re-
spectively. After neoadjuvant chemotherapy, she received breast 
conservation therapy and then adjuvant trastuzumab. Thirteen 
months later, local recurrent tumor was detected and she under-
went salvage mastectomy. EGFR, HER-3, HER-4, and IGF-1R of lo-
cal recurrent tumor was positive, negative, positive, and negative, 
respectively. Since then, she received lapatinib. However, lung me-
tastasis occurred 26 months later after initial diagnosis. EGFR, HER-
3, HER-4, and IGF-1R of systemic metastatic lesion was positive, 
positive, negative, and negative, respectively.
DISCUSSION
In our study, approximately three-fourths of HER-2 positive breast 
cancers expressed HER-4 and half of cases expressed EGFR and 
IGF-1R. The lowest proportion of one-thirds was determined in 
HER-3 expression. Previous studies have shown various positive 
rates of EGFR, HER-3, HER-4, and IGF-1R expression among HER-2 
positive breast cancers, which ranged from 18% to 56%, 9% to 
91%, 18% to 59%, and 26% to 44%, respectively [13-18]. Al-
though these wide frequencies of positive growth factor receptors 
family expression may be partly caused by the different character-
istics of study cohorts or the lack of standard methodology among 
reports, the present study also demonstrated similar results.
 Our study evaluated growth factor receptors family using whole 
sections of biopsy or surgical specimens and compared biomarkers 
between baseline status before administration of targeted agent and 
resistant tumor tissues to HER-2 targeted therapy. There were no 
significant associations of growth factor receptors family expression 
except EGFR between before and after administration of targeted 
therapy, which means a certain proportion of patients unpredictively 
changed in growth factor receptors expression compared to baseline 
status when recurrent or metastatic tumors were developed. Alter-
native growth factor receptors family signaling pathways could be 
involved in resistance to HER-2 targeted therapy [7], however, 
mechanisms would be very complex and possibly individualized.
 Various factors other than HER family and IGF-1R have been im-
plicated in resistance to HER-2 targeted therapy as follows: the 
HER-2 gene copy number, presence of p95-HER-2, Fc receptor poly-
morphisms, loss of phosphatase and tensin homolog (PTEN), down-
regulation of p27Kip1 expression, activation of mutations of PI3KCA 
gene, vascular endothelial growth factor receptor, heat shock protein 
90 (HSP90), activation of the cytoplasmic tyrosine kinase SRC, and 
mucin 4 glycoprotein expression [7,8,19,20]. However, recent bio-
marker analyses in CLEOPATRA trial showed that HER-2 was the 
only predictive marker for the use of trastuzumab plus pertuzum-
ab-based regimen as first-line treatment in HER-2 positive meta-
static breast cancer [21]. HER-2, HER-3 mRNA, and PIK3CA gene 
mutation were independent prognostic factors by multivariable 
analyses [21]. HER-3 mRNA was positively associated with favorable 
prognosis and PIK3CA mutation was negatively related to prognosis. 
 In our explorative study, higher positive expression of HER-3 was 
detected in good responders to targeted therapy, with a borderline 
statistical significance. In addition, by subgroup analysis of patients 
who treated with trastuzumab alone, 11 of 15 patients (73.3%) 
who experienced treatment failure showed negative HER-3 expres-
sion. Before administration of targeted agent, two patients with 
lung metastasis checked HER-3 expression in the primary and met-
astatic lesions and it was negative. These findings suggested that 
co-expression of HER-2 and HER-3 might be associated with favor-
able response to targeted therapy. However, further study with 
larger sample size is necessary to confirm our hypothesis and the 
prognostic and predictive roles of HER-3 expression in HER-2 posi-
tive breast cancers.
 Recently, IGF-1R is considered as one promising biomarker for 
overcoming resistance of HER-2 positive breast cancer. However, 
previous studies have demonstrated contradictory results regarding 
a potential role of IGF-1R in breast cancers [17,18,22]. In this study, 
no definitive roles of IGF-1R expression were shown in HER-2 posi-
tive breast cancers, however, in the subgroup analysis of HRs-posi-
tive diseases, IGF-1R expression was moderately correlated and 
might be a potential biomarker for overcoming resistance to HER-2 
directed therapy. In a recent study analyzed more than 1,100 pa-
tients, IGF-1R expression was frequently expressed in the luminal 
A/B subtype tumors and positive correlation of IGF-1R with prog-
nosis was demonstrated [18]. Phase II clinical trials of IGF-1R in-
hibitors are ongoing and these trial results will give a clue regarding 
the role of IGF-1R and the efficacy and safety of IGF-1R inhibitors 
in HER-2 positive breast cancer [19].
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 Major limitation of this study was that sample size was too small 
to derive definitive conclusions. During study periods, the costs of 
HER-2 targeted therapy were covered by national health insurance 
only in selected cases, therefore, a limited number of patients was 
able to be analyzed in this study. More importantly, immunohisto-
chemical detection or interpretation of growth factor receptors 
family has not been standardized. Further study is necessary.
 In conclusions, many HER-2 positive breast cancers overex-
pressed EGFR, HER-3, HER-4, or IGF-1R. A certain proportion of 
growth factor receptors family expression between before and after 
use of targeted therapy unpredictively showed discordant results, 
which suggested complex and personalized resistance mechanisms 
to HER-2 directed therapy. However, HER-3 expression might be 
associated with responsiveness to HER-2 targeted therapy. In the 
era of wide use of HER-2 directed therapy for HER-2 positive dis-
ease, it would be of importance the development of diagnostic and 
therapeutic strategies for overcoming resistance to HER-2 targeted 
therapy.
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